Search Results | Clinical Cancer Research | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer

Clin Cancer Res (2021) 27 (18): 5096–5108.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2915

Published: 15 September 2021

View article

Includes: Supplementary data

Journal Articles

In Memoriam: José Baselga's Journey in Cancer Medicine

Rakesh Kumar, Gabriel N. Hortobagy, Joan Albanell, Joaquín Arribas, Larry Norton

Clin Cancer Res (2021) 27 (12): 3499–3502.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-1624

Published: 15 June 2021

View article

Journal Articles

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

Clin Cancer Res (2020) 26 (6): 1432–1448.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-0353

Published: 13 March 2020

View article

Includes: Supplementary data

Journal Articles

NK Cell Infiltrates and HLA Class I Expression in Primary HER2⁺ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival

Aura Muntasell, Federico Rojo, Sonia Servitja, Carlota Rubio-Perez, Mariona Cabo, David Tamborero, Marcel Costa-García, María Martínez-Garcia, Sílvia Menéndez, Ivonne Vazquez, Ana Lluch, Abel Gonzalez-Perez, Ana Rovira, Miguel López-Botet, Joan Albanell

Clin Cancer Res (2019) 25 (5): 1535–1545.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-2365

Published: 01 March 2019

View article

Includes: Supplementary data

Journal Articles

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Clin Cancer Res (2018) 24 (7): 1536–1545.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1588

Published: 02 April 2018

View article

Includes: Supplementary data

Journal Articles

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer

Clin Cancer Res (2017) 23 (22): 7006–7019.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-0696

Published: 14 November 2017

View article

Includes: Supplementary data

Journal Articles

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Clin Cancer Res (2017) 23 (12): 3035–3044.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-2092

Published: 14 June 2017

View article

Includes: Supplementary data

Journal Articles

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Clin Cancer Res (2016) 22 (13): 3260–3267.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-2400

Published: 30 June 2016

View article

Includes: Supplementary data

Journal Articles

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

Clin Cancer Res (2015) 21 (9): 2157–2166.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-2821

Published: 30 April 2015

View article

Includes: Supplementary data

Journal Articles

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

Israel Cañadas, Federico Rojo, Álvaro Taus, Oriol Arpí, Montserrat Arumí-Uría, Lara Pijuan, Silvia Menéndez, Sandra Zazo, Manuel Dómine, Marta Salido, Sergi Mojal, Antonio García de Herreros, Ana Rovira, Joan Albanell, Edurne Arriola

Clin Cancer Res (2014) 20 (4): 938–950.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-1330

Published: 16 February 2014

View article

Includes: Supplementary data

Journal Articles

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Maria Martinez-Garcia, Udai Banerji, Joan Albanell, Rastilav Bahleda, Saoirse Dolly, Françoise Kraeber-Bodéré, Federico Rojo, Emilie Routier, Ernesto Guarin, Zhi-Xin Xu, Ruediger Rueger, Jean J. L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jean-Charles Soria

Clin Cancer Res (2012) 18 (17): 4806–4819.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0742

Published: 30 August 2012

View article

Includes: Supplementary data

Journal Articles

Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

Federico Rojo, Elías Gracias, Nadia Villena, Teresa Cruz, Josep Maria Corominas, Irene Corradino, Mercedes Cedeño, Clara Campas, Marta Osorio, Normando Iznaga, Beatriz Bellosillo, Ana Rovira, Silvia Marsoni, Pere Gascon, Sergio Serrano, Cristiana Sessa, Tania Crombet, Joan Albanell

Clin Cancer Res (2010) 16 (8): 2474–2482.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-3042

Published: 14 April 2010

View article

Journal Articles

Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin

Federico Rojo, Irene González-Navarrete, Rafael Bragado, Alba Dalmases, Silvia Menéndez, Maria Cortes-Sempere, Cristina Suárez, Cristina Oliva, Sonia Servitja, Vanesa Rodriguez-Fanjul, Isabel Sánchez-Pérez, Clara Campas, Josep Maria Corominas, Ignasi Tusquets, Beatriz Bellosillo, Sergi Serrano, Rosario Perona, Ana Rovira, Joan Albanell

Clin Cancer Res (2009) 15 (10): 3530–3539.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-2070

Published: 18 May 2009

View article

Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors

Joan Albanell, Clara Montagut, Eileen T. Jones, Linda Pronk, Begoña Mellado, Janette Beech, Pere Gascon, Gerhard Zugmaier, Michael Brewster, Mark P. Saunders, Juan W. Valle

Clin Cancer Res (2008) 14 (9): 2726–2731.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-1980

Published: 01 May 2008

View article

Journal Articles

Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity

Josep Domingo-Domenech, Cristina Oliva, Ana Rovira, Jordi Codony-Servat, Marta Bosch, Xavier Filella, Clara Montagut, Marian Tapia, Clara Campás, Lenny Dang, Mark Rolfe, Jeffrey S. Ross, Pere Gascon, Joan Albanell, Begoña Mellado

Clin Cancer Res (2006) 12 (18): 5578–5586.

DOI: https://doi.org/10.1158/1078-0432.CCR-05-2767

Published: 25 September 2006

View article

Journal Articles

p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

Rosana Sáez, Miguel A. Molina, Elizabeth E. Ramsey, Federico Rojo, Edward J. Keenan, Joan Albanell, Ana Lluch, Javier García-Conde, José Baselga, Gail M. Clinton

Clin Cancer Res (2006) 12 (2): 424–431.

DOI: https://doi.org/10.1158/1078-0432.CCR-05-1807

Published: 20 January 2006

View article

Journal Articles

ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells

Judit Anido, Pablo Matar, Joan Albanell, Marta Guzmán, Federico Rojo, Joaquin Arribas, Steve Averbuch, Jose Baselga

Clin Cancer Res (2003) 9 (4): 1274–1283.

Published: 01 April 2003

View article

Journal Articles

NH₂-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer

Miguel A. Molina, Rosana Sáez, Elizabeth E. Ramsey, María-José Garcia-Barchino, Federico Rojo, Adam J. Evans, Joan Albanell, Edward J. Keenan, Ana Lluch, Javier García-Conde, José Baselga, Gail M. Clinton

Clin Cancer Res (2002) 8 (2): 347–353.

Published: 01 February 2002

View article

NARROW

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer

In Memoriam: José Baselga's Journey in Cancer Medicine

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

NK Cell Infiltrates and HLA Class I Expression in Primary HER2⁺ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin

A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors

Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity

p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells

NH₂-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only